What is the Share Price of Bal Pharma Ltd?
- Answer Field
-
The share price of Bal Pharma Ltd for NSE is ₹ 102.15 and for BSE is ₹ 100.6.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, BAL PHARMA LTD. share price is currently at ₹ 102.15, which is down by ₹ -1.25 from its previous closing. Today, the stock has fluctuated between ₹ 100.20 and ₹ 107.59. Over the past year, BAL PHARMA LTD. has achieved a return of 3.12 %. In the last month alone, the return has been 13.70 %. Read More...
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 72.89 |
Operating Expense | 72.50 |
Net Profit | 1.16 |
Net Profit Margin (%) | 1.59 |
Earnings Per Share (EPS) | 0.73 |
EBITDA | 8.54 |
Effective Tax Rate (%) | 4.16 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 19.60 | 1.99 | 279.41 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 119.00 | 15.60 | 1.24 | 1253.91 | 92.25 / 184.95 |
CIPLA LTD | 1549.65 | 25.08 | 4.41 | 125155.99 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 260.70 | 21.60 | 2.64 | 767.27 | 145.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 21.96 | 6.19 | 279.41 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 692.80 | 40.61 | 6.72 | 2002.93 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8665.50 | 129.24 | 31.88 | 21663.75 | 5000.00 / 9199.00 |
BLISS GVS PHARMA LTD | 119.00 | 15.45 | 1.22 | 1253.91 | 92.25 / 184.95 |
Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May '87. In Mar.'90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations.
BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.
During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The company's product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM.
The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named 'SERVETUS' has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002.
The commercial production of Formulation Plant in Uttarakhand started from 1st January, 2009. The Company floated Lifezen Healthcare Pvt Ltd during the year 2014-15 as its subsidiary. It ventured into heath care sector through its subsidiary i.e. Balance Clinics LLP. In 2016-17, it commenced its project on construction of an fully integrated API unit with an annual production capacity of 270 metric tonnes of assorted API products including Gliclazide, Ebastine, Amiloride HCL, Benzydamine HCL, Pregablin etc, located at Gauribidanur near Bangalore with an estimated investment of Rs 45 Crores.
In 2017-18, the Company acquired 100% stake and management control of Golden Drugs Private Ltd, an Udaipur, Rajasthan involved in the manufacture of bulk drugs and intermediates costing Rs 14 Crores. It earmarked Rs. 36 Cr. for setting up of an bulk drug's
manufacturing unit at Yadgir District , Karnataka in year 2022-23. It launched Sitagliptin (a DPP-4 Inhibitor) in the plain form, and as a combination with Metformin under the brand names SITABEND & SITABEND-M, respectively in 2023.
The share price of Bal Pharma Ltd for NSE is ₹ 102.15 and for BSE is ₹ 100.6.
The market cap of Bal Pharma Ltd for NSE is ₹ 1,61.44 Cr. and for BSE is ₹ 1,58.99 Cr. as of now.
The 52 Week High and Low of Bal Pharma Ltd for NSE is ₹ 157.98 and ₹ 78.06 and for BSE is ₹ 157.90 and ₹ 76.30.
You can trade in Bal Pharma Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been 3.12%.
Bal Pharma Ltd share price is for NSE ₹ 102.15 & for BSE ₹ 100.6 as on Apr 30 2025 03:30 PM.
The market cap of Bal Pharma Ltd for NSE ₹ 1,61.44 & for BSE ₹ 1,58.99 as on Apr 30 2025 03:30 PM.
As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Bal Pharma Ltd share is 15.71.
As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Bal Pharma Ltd share is 67.04.
You can trade in Bal Pharma Ltd shares with Bajaj Broking by opening a demat account.
To buy Bal Pharma Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Bal Pharma Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found